Genmab — Marts 2018

[E_L]

thank you!

[pauly]

Forget Remicade -- Here's How Johnson & Johnson Plans to Grow

Three ways the healthcare giant intends to keep its pharma business growing despite declining sales for its top-selling drug.

Yahoo Finance (finance.yahoo.com)

[pauly]

Darzalex highligtet

[pauly]

As for Darzalex, Duato stated that J&J has a "very ambitious development program" for the drug. He said that Darzalex already claims a market share of around 20% as a second-line treatment for multiple myeloma. The "next wave of growth" for the drug will be in the first-line setting, according to Duato. He said J&J considers the drug as a backbone therapy in multiple myeloma.

[StockBull]

Morning fra Thailand.

[StockBull]

Det her med Dara Rosen reducere fra 90 ml til 15 ml hvordan skal det forstaar. Vil det medfoere at Dara salget falder mon ?og er
det mon derfor shorterne stadig er aktive

[StockBull]

Just a moment...

(journals.lww.com)

[Helge_LarsenPI-redaktør]

God morgen.

[Plimsoller]

God morgen

[bibob]

God morgen

[bibob]

Når Dara bliver first Line vil der alt andet lige blive brugt mere. Læg mærke til den næst sidste linie i linket StockBull " that's a lot of Dara being used globaly "

[polle1]

God morgen

[pauly]

mornings

[transalp]

go morgen : )

[Bulder]

StockBull: Der indgår stadig 1800 mg dara. Men blandingsvæsken med hyaluronidase er mere koncentreret nu (15 ml) end før, hvor blandingen skulle mixes manuelt og kom helt op på 90 ml i blandt. Så stor mængde blandingsvæske skulle indgives med en sprøjtepumpe og tog længere tid.

[E_L]

i would think you can safely assume that 1 dose of Dara SC will cost (at least) the same as 1 dose of Dara IV, irrespective of how much ml is in that dose

[Bulder]

Yes because the amount of dara is the same.

[Bulder]

For lige at præcisere: Mængden af dara er den samme (1800 mg) uanset om man blander manuelt med hyaluronidase på klinikken og får op til 90 ml, eller om man modtager det pre-mixed fra fabrikken i 15 ml færdige doser.

[Raffles]

På AACR har BMS et Abstract #2603 (….colorectal cancer treated with Nivolumab + Ipilimumab in checkmate -142, 16. april). De øvrige drugs (DARA og Cobimetinib) står dog ikke nævnt i overskriften!
Endvidere har de Abstract #1727 (antitumor actitity associated with dual targeting of CD38 and PD-1 pathways in preclinical models, 16. april).
Mon der kommer noget brugbart nyt d. 16. april??

[E_L]

i wast just reading this one " Furthermore, TTI-622 potentiates the efficacy of daratumumab and cetuximab in hematological and solid xenograft tumor models, respectively" http://www.abstractsonline.com/pp8/#!/4562/presentation/9327